Characterization of Myeloid Cell Hyperactivation Syndrome and Survival Differences...

Presented By: Elinor Willis, VMD, PhD, DACVP
Speaker Biography: Dr. Elinor Willis received her veterinary degree and PhD from the University of Pennsylvania. Her PhD work focused on antiviral immunity and vaccines in infant mouse models. She then completed her residency in veterinary anatomic pathology at the University of Pennsylvania and is a diplomate of the American college of Veterinary Pathologists.

She is currently a fellow with the Comparative Pathology Core at UPenn with interests in animal models, immunology, cellular and antibody-mediated therapies, and infectious diseases.
Webinar: Characterization of Myeloid Cell Hyperactivation Syndrome and Survival Differences in Humanized NOG-EXL and NSG-SGM3 Mice
Webinar Abstract: Super immunodeficient mice such as the NOG-EXL and NSG-SGM3 combine severe immunodeficiency with transgenic expression of human myeloid-stimulatory cytokines. These mouse strains support an improved expansion of human myeloid cell populations following engraftment with human CD34+ hematopoietic stem cells (HSC). The application of these valuable humanized immune system (HIS) models can be complicated by adverse events that limit their use in long-term studies.

In this webinar, Dr. Elinor Willis will cover the characterization of myeloid cell hyperactivation syndrome in CD34+ HSC-humanized NSG-SGM3 and NOG-EXL mice, including significant new histopathology data in various tissues. Learn about important differences in overall survival and severity of myeloid cell hyperactivation syndrome between strains. These differences are relevant to selecting the most appropriate HIS model for longer-term studies.
Labroots on Social:
Facebook:   / labrootsinc  
Twitter:   / labroots  
LinkedIn:   / labroots  
Instagram:   / labrootsinc  
Pinterest:   / labroots  
SnapChat: labroots_inc